BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 36334015)

  • 61. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
    García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F
    J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparison of fecal calprotectin and serum C-reactive protein in early prediction of outcome to infliximab induction therapy.
    Engström J; Lönnkvist M; Befrits R; Ljung T; Diaz-Tartera H; Holst M; Hellström PM
    Scand J Gastroenterol; 2019 Sep; 54(9):1081-1088. PubMed ID: 31499013
    [No Abstract]   [Full Text] [Related]  

  • 63. Fecal calprotectin as a marker of the severity of mucosal inflammation in children with inflammatory bowel disease.
    Dolinšek J; Rižnik P; Sabath L; Mičetić-Turk D
    Wien Klin Wochenschr; 2016 Apr; 128(7-8):253-9. PubMed ID: 26659704
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis.
    Urushikubo J; Yanai S; Nakamura S; Kawasaki K; Akasaka R; Sato K; Toya Y; Asakura K; Gonai T; Sugai T; Matsumoto T
    World J Gastroenterol; 2018 Oct; 24(38):4384-4392. PubMed ID: 30344422
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Leucine-Rich Alpha-2 Glycoprotein May Be Predictive of the Adalimumab Trough Level and Antidrug Antibody Development for Patients with Inflammatory Bowel Disease: A Sub-Analysis of the PLANET Study.
    Yanai S; Shinzaki S; Matsuoka K; Mizuno S; Iijima H; Naka T; Kanai T; Matsumoto T
    Digestion; 2021; 102(6):929-937. PubMed ID: 34350873
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers.
    Ricanek P; Brackmann S; Perminow G; Lyckander LG; Sponheim J; Holme O; Høie O; Rydning A; Vatn MH;
    Scand J Gastroenterol; 2011 Sep; 46(9):1081-91. PubMed ID: 21619483
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Rapid fecal calprotectin level assessment and the SIBDQ score can accurately detect active mucosal inflammation in IBD patients in clinical remission: a prospective study.
    Voiosu T; Benguş A; Dinu R; Voiosu AM; Bălănescu P; Băicuş C; Diculescu M; Voiosu R; Mateescu B
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):273-8. PubMed ID: 25267955
    [TBL] [Abstract][Full Text] [Related]  

  • 68. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis.
    Mosli MH; Zou G; Garg SK; Feagan SG; MacDonald JK; Chande N; Sandborn WJ; Feagan BG
    Am J Gastroenterol; 2015 Jun; 110(6):802-19; quiz 820. PubMed ID: 25964225
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease.
    Pinto-Lopes P; Afonso J; Pinto-Lopes R; Rocha C; Lago P; Gonçalves R; Tavares De Sousa H; Macedo G; Camila Dias C; Magro F
    Inflamm Bowel Dis; 2020 Oct; 26(11):1707-1719. PubMed ID: 31912883
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Fecal short chain fatty acids and urinary 3-indoxyl sulfate do not discriminate between patients with Crohn´s disease and ulcerative colitis and are not of diagnostic utility for predicting disease severity.
    Tews HC; Elger T; Gunawan S; Fererberger T; Sommersberger S; Loibl J; Huss M; Liebisch G; Müller M; Kandulski A; Buechler C
    Lipids Health Dis; 2023 Oct; 22(1):164. PubMed ID: 37789460
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization.
    Fukunaga S; Kuwaki K; Mitsuyama K; Takedatsu H; Yoshioka S; Yamasaki H; Yamauchi R; Mori A; Kakuma T; Tsuruta O; Torimura T
    Int J Mol Med; 2018 Jan; 41(1):107-118. PubMed ID: 29115397
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Fecal Calprotectin Thresholds to Predict Endoscopic Remission Using Advanced Optical Enhancement Techniques and Histological Remission in IBD Patients.
    Cannatelli R; Bazarova A; Zardo D; Nardone OM; Shivaji U; Smith SCL; Gkoutos G; Ricci C; Gui XS; Ghosh S; Iacucci M
    Inflamm Bowel Dis; 2021 Apr; 27(5):647-654. PubMed ID: 32592477
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Fecal Human Neutrophil Peptide Levels Correlate with Intestinal Inflammation in Ulcerative Colitis.
    Kanmura S; Hamamoto H; Morinaga Y; Oda K; Fujita T; Arima S; Nasu Y; Sasaki F; Hashimoto S; Taguchi H; Setoyama H; Ido A
    Digestion; 2016; 93(4):300-8. PubMed ID: 27220673
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.
    Gisbert JP; Bermejo F; Pérez-Calle JL; Taxonera C; Vera I; McNicholl AG; Algaba A; López P; López-Palacios N; Calvo M; González-Lama Y; Carneros JA; Velasco M; Maté J
    Inflamm Bowel Dis; 2009 Aug; 15(8):1190-8. PubMed ID: 19291780
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The combination of fecal calprotectin with ESR, CRP and albumin discriminates more accurately children with Crohn's disease.
    Daniluk U; Daniluk J; Krasnodebska M; Lotowska JM; Sobaniec-Lotowska ME; Lebensztejn DM
    Adv Med Sci; 2019 Mar; 64(1):9-14. PubMed ID: 30237086
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
    Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
    Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Novel Utility of Leucine-Rich Alpha-2-Glycoprotein as a Biomarker in Ulcerative Colitis: A Predictor of Endoscopic Remission Independent of Symptoms.
    Hayashi T; Kitamura K; Usami M; Miyazawa M; Nishitani M; Dejima A; Yamamoto M; Kawase S; Funaki M; Orita N; Nakagawa H; Morita K; Iida N; Seki A; Nio K; Kido H; Takayama H; Takeuchi Y; Yamada S; Takatori H; Shimada M; Saito H; Yamamoto D; Toyama T; Yamashita T
    Inflamm Intest Dis; 2023 Dec; 8(4):133-142. PubMed ID: 38115911
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Serum calprotectin as a biomarker for Crohn's disease.
    Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
    J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Disease monitoring in inflammatory bowel disease.
    Chang S; Malter L; Hudesman D
    World J Gastroenterol; 2015 Oct; 21(40):11246-59. PubMed ID: 26523100
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comparison of three commercial fecal calprotectin ELISA test kits used in patients with Inflammatory Bowel Disease.
    Mirsepasi-Lauridsen HC; Bachmann Holmetoft U; Ingdam Halkjær S; Angeliki Krogfelt K; Munk Petersen A
    Scand J Gastroenterol; 2016; 51(2):211-7. PubMed ID: 26359672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.